Ezequiel Gleichgerrcht
Epilepsy · Atlanta, GANPI 1851779318
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 74.8% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $8,416, 9.0 times the $940 reported in 2022.
Across 28 payments — averaging $349.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Neuropace, Inc.$1K
- DIXI Medical USA Corp$824
- Jazz Pharmaceuticals Inc.$258
- UCB, Inc.$175
Across 2 payments — averaging $1466.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$3K
What the payments were for
- Consulting fees$1,35014%
- Speaking & faculty fees$5,06352%
- Travel & lodging$8879%
- Food & beverage$2,49825%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $7,331 |
| Neuropace, Inc. | 8 | $1,210 |
| DIXI Medical USA Corp | 1 | $824 |
| Jazz Pharmaceuticals Inc. | 2 | $258 |
| UCB, Inc. | 3 | $175 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VISUALASE$4,866
- PERCEPT PC BRAINSENSE$2,018
- RNS Neurostimulator Kit$1,096
- Epidiolex$142
How this compares
Too few epilepsy providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 21 | $949 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Atlanta
- Rebecca MatthewsAtlanta$7K
- Katie BullingerAtlanta$4K
- Ekta ShahAtlanta$3K
- Aida RismanAtlanta$2K
- Daniel WinkelAtlanta$706
- Brian CabanissAtlanta$241
- Charles EpsteinAtlanta$158
- Danielle WeissAugusta$5K
- Kohilavani VelayudamDuluth$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.